| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.84B | 5.72B | 6.79B | 6.53B | 4.74B | 3.57B |
| Gross Profit | 1.25B | 1.28B | 1.65B | 1.53B | 1.24B | 883.11M |
| EBITDA | 810.19M | 1.01B | 1.48B | 1.41B | 1.20B | 776.48M |
| Net Income | 107.77M | 278.88M | 647.73M | 737.69M | 650.91M | 296.82M |
Balance Sheet | ||||||
| Total Assets | 10.45B | 10.07B | 11.06B | 9.20B | 6.13B | 5.61B |
| Cash, Cash Equivalents and Short-Term Investments | 91.49M | 75.97M | 126.50M | 127.02M | 68.91M | 81.62M |
| Total Debt | 4.34B | 4.26B | 4.64B | 3.58B | 1.62B | 1.66B |
| Total Liabilities | 5.68B | 5.61B | 6.37B | 5.31B | 2.79B | 2.66B |
| Stockholders Equity | 4.69B | 4.38B | 4.61B | 3.81B | 3.28B | 2.89B |
Cash Flow | ||||||
| Free Cash Flow | 476.11M | 506.81M | 342.26M | 420.94M | 430.02M | 340.73M |
| Operating Cash Flow | 773.50M | 839.29M | 899.26M | 813.74M | 704.42M | 624.65M |
| Investing Cash Flow | -495.80M | -498.90M | -1.68B | -2.42B | -490.26M | -310.63M |
| Financing Cash Flow | -332.23M | -399.56M | 876.29M | 1.68B | -221.36M | -306.99M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | ― | ― | ― | ― | -1.19% | 78.79% | |
73 Outperform | $9.49B | 7.74 | 31.76% | ― | 1.81% | 24.67% | |
69 Neutral | $5.79B | 54.79 | 2.33% | ― | -0.83% | -58.55% | |
67 Neutral | $3.82B | 19.04 | ― | ― | 16.05% | -10.17% | |
65 Neutral | $7.14B | 11.20 | 16.10% | 2.86% | -3.83% | -2.04% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
60 Neutral | $8.31B | 28.64 | 16.22% | 2.48% | <0.01% | -51.18% |
On December 10, 2025, Darling Ingredients Inc. announced a definitive agreement with Tessenderlo Group to form a joint venture, combining their collagen and gelatin business segments into a new company, NewCo Collagen LLC. Darling will hold an 85% stake, while Tessenderlo will hold 15%, with expected annual revenue of $1.5 billion. The venture aims to capitalize on the growing collagen market, leveraging synergies and expanding the Nextida product portfolio. The transaction, pending regulatory approvals, is expected to close in 2026, enhancing growth opportunities and shareholder value for Darling Ingredients.
On November 10, 2025, Darling Ingredients Inc. announced the upcoming retirement of John F. Sterling, the Executive Vice President, General Counsel and Secretary, effective March 31, 2027. Sterling will continue in his current role until January 4, 2026, after which Nick Kemphaus will take over his responsibilities. Sterling will remain in an advisory role until his retirement, with a salary adjustment and exclusion from incentive programs. Kemphaus, with over 20 years of legal experience, has been with the company since 2012, handling various legal and regulatory matters.
On September 26, 2025, Matt Jansen, the Chief Operating Officer for North America at Darling Ingredients, departed from his role. His departure qualifies him for severance benefits under the Senior Executive Termination Benefits Agreement, contingent upon his compliance with specific terms, as outlined in the company’s 2025 Proxy Statement.